Big announcement

1. China Exempt plans to invest an additional 1.07 billion yuan in the Sanya International Duty Free City Phase I Site 2 project

$CTG DUTY-FREE (01880.HK)$It was announced that in March 2021, after review and approval by the board of directors, the company invested RMB 3.69 billion for the construction of the Sanya International Duty Free City Phase I Site 2 project. As the development of the project progresses, in order to further enhance the overall competitiveness of the project, after considering various factors such as product positioning, market conditions and actual progress of the project, the company plans to invest an additional RMB 1.07 billion in the project, mainly to increase the construction area, parking area, exterior and curtain wall quality, and improve the configuration of mechanical and electrical systems and power systems.

2. Country Garden was liquidated by Ever Credit to recover $1.6 billion in unpaid loans and interest

$COUNTRY GARDEN (02007.HK)$Announced, Ever Credit filed a winding-up petition against the company with the Hong Kong High Court yesterday, relating to unpaid term loans and accrued interest between the petitioner and the company with a principal amount of about $1.6 billion. Currently, the High Court has not issued a winding-up order to wind up the company. The High Court has set the date for the first hearing of the petition on May 17. The company stated that it will vigorously oppose the petition, consult legal opinions, and take all necessary actions to protect its legal rights.

3. Nine Dragons Paper announced interim results. Shareholders' profit attributable to shareholders was 292 million yuan, turning a year-on-year loss into a profit

$ND PAPER (02689.HK)$Announcing results for the six months ended December 31, 2023, the group obtained revenue of RMB 30.611 billion (same unit), a year-on-year decrease of 1.9%; profit attributable to the company's equity holders of RMB 292 million, compared with a loss of RMB 1,389 million for the same period last year; and profit of RMB 0.06 per share.

4. Fuzhikang Group issued a profit warning and is expected to have a consolidated net loss of about US$120.8 million in 2023

$FIH (02038.HK)$Currently, revenue for 2023 is estimated to be approximately US$6.446 billion, down 31.4% year on year, and comprehensive net loss of 120.8 million yuan, up 67.55% year on year. Mainly because mobile phone shipments hit their lowest level in ten years, the decline in sales led to a decline in gross profit.

5. Shijiyao Group: Gliclazide tablets (80mg) passed the consistent evaluation of generic drug quality and efficacy

$SSY GROUP (02005.HK)$According to the announcement, the Group's Gliclazide tablets (80mg) have obtained approval from the China National Drug Administration to pass the consistent evaluation of the quality and efficacy of generic drugs. Gliclazide tablets are mainly used in adults with type 2 diabetes when diet control, physical exercise, and weight loss alone are insufficient to control blood sugar levels.

Earnings Report

$JNBY (03306.HK)$Released interim results, profit of 574 million yuan increased 54.45% year over year

$SCHOLAR EDU (01769.HK)$Positive profit forecast issued: The adjusted net profit for fiscal year 2023 is expected to be no less than 100 million yuan, a significant increase of 83.8% over last year

$IMAX CHINA (01970.HK)$: Adjusted profit for fiscal year 2023 reached US$29.8 million

Operational data

$SUNKWAN PPT (06900.HK)$: The contract sales amount for January is about 120 million yuan

$ZAI LAB (09688.HK)$: Product revenue for the full year of 2023 was US$266.7 million

$ASMPT (00522.HK)$: Sales revenue of HK$14.7 billion for the full year of 2023 decreased by 24.1% year-on-year

Pharmaceutical Innovation

$ABBISKO-B (02256.HK)$: Preliminary results of the first human clinical trial of the FGFR2/3 highly selective inhibitor ABSK061 were presented orally at ESMO TAT in 2024

$CUTIA-B (02487.HK)$: CU-20401 (recombinant mutant collagenase) treatment of abdominal fat accumulation completed phase I clinical trial in China

Equity incentives

$APOLLO FMG (00860.HK)$Grants 48 million share options

Increase or decrease holdings

$HUA HONG SEMI (01347.HK)$: Huahong Group has increased its total holdings by 1.2 million shares, and the implementation of the company's A share increase plan has been completed

Repurchase cancellation

$AIA (01299.HK)$2,568,600 shares were repurchased at HK$162 million on February 27

$HSBC HOLDINGS (00005.HK)$2.2972 million shares were repurchased at HK$137 million on February 26

$KUAISHOU-W (01024.HK)$On February 27, 885,000 shares were repurchased at HK$39.99 million

$SWIRE PACIFIC A (00019.HK)$On February 27, 294,000 shares were purchased at HK$18.65 million

$YUM CHINA (09987.HK)$On February 26, 40,200 shares were purchased at HK$13.306 million

$HAIER SMARTHOME (06690.HK)$On February 27, it spent 9.538,900 yuan to buy back 400,000 A-shares

edit/ruby